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Flaviviruses are emerging threats to public health worldwide. Recently, one flavivirus, West Nile virus (WNV), has caused the largest
epidemic of viral encephalitis in US history. Like other flaviviruses, WNV is thought to cause a persistent infection in insect cells, but an
acute cytopathic infection of mammalian cells. To study adaptation of WNV to persistently replicate in cell culture and generate a system
capable of detecting antiviral compounds in the absence of live virus, we generated subgenomic replicons of WNV and adapted these to
persistently replicate in mammalian cells. Here we report that adaptation of these replicons to cell culture results in a reduction of genome
copy number, and demonstrate that hamster, monkey, and human cells that stably carry the replicons can be used as surrogates to detect the
activity of anti-WNV compounds. Additionally, we have used these cells to investigate the interaction of WNV genomes with interferon
(IFN). These studies demonstrated that IFN can cure cells of replicons and that replicon-bearing cells display lower responses to IFN than
their IFN-cured derivatives.
D 2004 Elsevier Inc. All rights reserved.
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West Nile virus (WNV) is a member of the Flavivirus
genus of the family Flaviviridae. Members of this genus
include several important arthropod-borne pathogens, includ-
ing dengue virus (DV), Japanese encephalitis virus (JEV),
tick-borne encephalitis virus (TBEV), and yellow fever virus
(YFV). WN encephalitis, a rare outcome of infection with0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.10.046
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Agriculture, PO Box 848, Greenport, NY 11944-0848, USA.WNV, was observed periodically in Asia, Africa, the Middle
East, and Europe in the years following the original isolation
of the virus in 1937 from awoman suffering from amild fever
(Smithburn et al., 1940). Following its introduction into the
US in 1999, WNV was responsible for approximately 150
human cases and 18 fatalities through 2001 (Campbell et al.,
2002). However, in 2002, the US Centers for Disease Control
and Prevention reported over 4000 laboratory-confirmed
human infections with greater than 280 deaths and virus
activity in over 40 states. While the number of laboratory-
confirmed cases rose in 2003, the number of deaths was
similar to that reported in 2002. Although there are efforts
underway to produce a vaccine to prevent WN encephalitis in
man (Monath, 2001), the most important target population for
this vaccine (the elderly) is small, development costs are
significant, and preparation time for a vaccine that could be
used in man is substantial, making antiviral development a
useful public health alternative to vaccination.05) 457–470
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which is proteolytically processed into approximately a
dozen functional proteins by both viral and cellular proteases
(Chambers et al., 1990). The 5V terminal 2.5 kb of the viral
RNA encodes the three flavivirus structural proteins: capsid
(C), membrane (M; which exists in cells as its precursor,
prM), and envelope (E). The nonstructural proteins, encoded
by the remainder of the polyprotein, are designated NS1,
NS2A, NS2B, NS3, NS4A, NS4B, andNS5 (Chambers et al.,
1990). Infectious cDNAs for flaviviruses have been available
for over a decade and have been utilized to probe many
interesting aspects of viral function. Subgenomic RNAs
capable of replicating within cells (replicons) have been
reported for Kunjin virus (KV) (Khromykh and Westaway,
1997), WNV (Shi et al., 2002a), YFV (Corver et al., 2003;
Molenkamp et al., 2003), DV (Pang et al., 2001), and TBEV
(Gehrke et al., 2003). All of these replicons have a similar
genetic structure: they include the 5V untranslated region
(UTR), a portion of the C coding region (containing a
cyclization domain), a polyprotein encoding NS1 through
NS5, and the 3V UTR. When introduced into cells, these
subgenomic RNAs are able to replicate and reporter genes
have been inserted into the replicons to follow their
replication (Khromykh and Westaway, 1997; Shi et al.,
2002a). Interestingly, both KV and WNV replicons are
reported to be noncytopathic following their introduction
into baby hamster kidney (BHK) cells (Khromykh and
Westaway, 1997; Shi et al., 2002a). Vero cells persistently
infected with KV replicons have also been reported (Mack-
enzie et al., 2001). In the case of DV, primate cells
transfected with DV replicons were reported to express
antigen for up to 8 days without a selectable marker gene
(Pang et al., 2001). Recently, Lo et al. (2003b) have reported
that BHK cells stably replicating WNV replicons harboring
a Renilla luciferase gene could be used for identification of
antiviral compounds.
There have been a number of reports indicating that
antiviral compounds can control flavivirus infections, sup-
porting the contention that antiviral drugs could be useful in
combating the emerging public health threat produced by
WNV infection. Several nucleoside analogues and com-
pounds that interfere with nucleoside synthesis have been
shown to have anti-flavivirus activity in vitro (Anderson and
Rahal, 2002; Huggins, 1989; Huggins et al., 1984; Jordan et
al., 2000; Markland et al., 2000; Morrey et al., 2002).
However, studies of these types of compounds in vivo are
limited, and studies with the best-characterized compound in
this group, ribavirin, failed to demonstrate any effect on DV
titers (Malinoski et al., 1990) or any alteration in signs of
yellow fever (Huggins, 1989) in monkeys. Interferon (IFN)
has also been shown to be effective against many different
flaviviruses in vitro (Anderson and Rahal, 2002; Diamond
and Harris, 2001; Luby, 1975; Yasuda et al., 2000). Addi-
tionally, several IFN-inducing compounds, such as poly-
dI-dC, have been useful in treating flavivirus disease in
animals (Haahr, 1971; Harrington et al., 1977; Luby, 1975;Sarzotti et al., 1989; Stephen et al., 1977; Taylor et al., 1980).
However, IFN or IFN-inducing drugs are only effective if
delivered immediately before, or soon after the onset of in-
fection. Therefore, it appears that these compounds may only
be effective during the amplification of virus that precedes
the virus’ transit of the blood–brain barrier, in the case of
encephalitic viruses (Brooks and Phillpotts, 1999; Taylor et
al., 1980), or entry into the liver, in the case of YFV (Stephen
et al., 1977). Furthermore, a recent study of the clinical
effectiveness of IFN a 2a in JE patients failed to demonstrate
any benefit from the therapy (Solomon et al., 2003).
Despite the apparent limitation for use of IFN in treating
flavivirus infection, IFN action is clearly important in
determining the outcome of flavivirus infections. Recently,
works onMurray Valley encephalitis virus (MVEV; Lobigs et
al., 2003) and DV (Johnson and Roehrig, 1999; Shresta et al.,
2004) have demonstrated that mice with deficits in the IFN
a/h receptor are more susceptible to flavivirus infection.
Moreover, work byMunoz-Jordan et al. (2003) indicated that
several DV proteins, when expressed individually, could alter
the ability of IFN to activate an antiviral response in human
cells. This study pointed in particular to NS2A, NS4A, and
NS4B as expressing activities that could protect viral
replication from the IFN-induced antiviral defense mecha-
nism of the host cell (Munoz-Jordan et al., 2003).
Here we describe the generation of an infectious cDNA
and replicon for WNV from a human isolate of WNV and
demonstrate that multiple cell types can be generated that
persistently carry the replicon. In our derivation of these
cells, we discovered that during the establishment of
persistence, replicon levels were reduced in these cells.
Furthermore, in some cell types, the generation of cell lines
harboring replicons was more difficult, suggesting that an
equilibrium between the replicon genome and the host cell
was required to produce stable cell lines. Following isolation
of replicon-bearing cell lines, these cells stably maintained
the replicons for dozens of passages, and these lines could be
used to evaluate antiviral activity of both nucleoside
analogues and IFN. These latter results are particularly
interesting, since they indicate that replicon expression did
not prevent IFN from eliminating the replicon from these
cells. However, evaluation of the antiviral action of IFN in
replicon-bearing cells demonstrated that relative to WT and
IFN-cured cells, the replicon-bearing cells displayed a
reduced response to IFN that is consistent with the recent
report that DV nonstructural proteins can inhibit IFN
activation of its target genes (Munoz-Jordan et al., 2003).Results
Cloning of a replicon and infectious cDNA from a human
isolate of WNV
RNA extracted from WNV-infected Vero cells was
reverse transcribed and fragments were amplified following
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infectious cDNA and replicon from the NY strain of WNV
(see Materials and methods and Fig. 1; Shi et al., 2002a,
2002b). The individual DNA fragments were inserted into a
high-copy plasmid (see Materials and methods). From the
resulting recombinant plasmids, one or two were selected
for each fragment, and their ends were sequenced and
compared to a number of WNV sequences (Lanciotti et al.,
2002). A significant difference was only identified in one
cDNA clone, and this clone was discarded. From the
remaining plasmids, a single representative selected for each
region of the genome was used for all subsequent studies.
Attempts to assemble all five genome fragments into a high-
copy plasmid failed to produce recombinant plasmids with
more than four fragments. However, these fragments were
readily assembled into a low-copy plasmid pACNR (see
Materials and methods). BHK cell cultures transfected with
RNAs transcribed from XbaI-linearized, mung bean exonu-
clease-treated templates prepared from three independent
recombinant plasmids assembled in the pACNR plasmid
were strongly immunoreactive with anti-WNV sera. From
these three plasmids, a single replicon-encoding plasmid
was selected for all further characterization. Although
electroporations with this replicon yielded antigen-positive
cells, the frequency of obtaining these cells was low, with
only 0.1–1% of electroporated BHK cells producing
immunochemically detectable antigen. To increase trans-
fection efficiency, a hepatitis delta virus ribozyme (HDV-
RZ) was added to the cDNA copy of the genome using a
strategy employed for a variety of positive-strand RNA
viruses. The addition of the HDV-RZ improved the
efficiency of establishing RNA replication by 20- to 100-
fold over the XbaI-linearized, exonuclease-polished tran-
scripts, routinely yielding electroporation efficiencies of
over 30% on BHK cells stained at 48 h postelectroporation,
confirming the value of addition of the ribozyme to generate
a precise 3V end on the T7-transcribed RNA.Fig. 1. (Panel A) Schematic representation of the WNV genome showing the pos
replicon construction. (Panel B) Schematic representation of WNV replicon showi
infectious cDNA and the position of theminipolyprotein gene cassette. Oligonucleoti
alongwith the naturally occurring (BspEI, SmaI, SpeI,NsiI) and synthetic (BamHI,AA full-length cDNA clone (FLC) was obtained from
this prototype replicon by the single-step insertion of a
PCR-amplified C/prM/E cassette of WNV (Fig. 1).
Synthetic RNA obtained from this FLC was infectious
in BHK cells as shown by the recovery of virus with titers
of 1  109 pfu/ml 2–3 days postelectroporation. Fur-
thermore, analyses of the comparative infectivities of the
HDV-RZ-encoding and bprototypeQ FLC demonstrated that
the HDV-RZ increased specific infectivity by about 20-
fold, making our HDV-RZ-encoding WNV FLC similar in
infectivity to those recently reported for YFV (Bredenbeek
et al., 2003) and JEV (Yun et al., 2003). Sequence
analysis of this FLC identified only two nucleotide differ-
ences with the sequence obtained directly from PCR-
amplified fragments of a parallel passage of the same
human isolate of WNV (provided by B.P. Granwehr and
A.D.T. Barrett). One of these changes was a silent change
intentionally introduced at the AflII site used to construct
the replicon (Fig. 1), and the second change, also silent,
was in NS1. The sequence of our cDNA showed a small
number of differences compared to the sequence of a 1999
flamingo isolate (GenBank accessionAF196835); we found
no deletions and insertions, no difference in 5V UTR, 30
differences in the polyprotein-encoding sequence, 25 of
which were silent, and three changes in 3V UTR. The five
coding differences detected were as follows: Thr–Ala
(AccYGcc) at E protein codon 76, Glu–Gly (gAgYgGg)
at NS1 codon 94, Val–Ile (GtaYAta) at NS2A codon 138,
Val–Ile (GttYAtt) at NS4B codon 161, and Thr–Ile
(aCcYaTc) at NS5 codon 526.
Isolation of BHK cell lines persistently expressing replicon
genomes
Our prototype replicon was modified by inserting a
bminipolyproteinQ gene cassette (Yi et al., 2002) encoding
the HIV tat gene (or a modified form of this cassette initions of synthetic oligonucleotides, restriction sites, and fragments used for
ng the position of the oligonucleotides and fragments used to reconstruct an
des are indicated by arrows; PCR-amplified fragments are shown by bold lines,
flII, andXbaI) restriction sites that were used to assemble the cDNA fragments.
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firefly luciferase (Luc) genes replaced tat), linked to the
short FMDV autocatalytic protease 2A, and neomycin
phosphotransferase II (NPT) into an NsiI site present in
the cDNA encoding the replicon’s 3V UTR. Making use of
the antibiotic resistance phenotype of cells expressing NPT,
cells carrying this replicon were selected by treating
electroporated cultures of BHK with 400 Ag/ml of G418.
Stable BHKs were readily obtained using this selection
method, with up to 10% of the cells that expressed antigen
at 48 h postelectroporation yielding G418-resistant colonies.
Using these methods, clonally derived cell lines harboring
derivatives of the replicon containing tat, eGFP, or Luc
(linked via fusion to 2A, permitting cleavage from the
selectable marker gene NPT) were obtained. In these same
analyses, we noted that the specific infectivity of the
synthetic RNA (as measured by the detection of antigen-
positive cells 48 h postelectroporation) was reduced by the
addition of the reporter genes in the 3V UTR. The observed
reductions in specific infectivity (2- to 100-fold, with lower
efficiencies detected with larger reporter gene constructs)
did not prevent the selection of replicon-containing colonies
of BHK cells that were resistant to G418, and are consistent
with the work of Varnavski and Khromykh (1999) showing
an effect of reporter gene insertion on specific infectivity of
KV replicons. Interestingly, following isolation of G418-
resistant cells, the levels of WNV antigen and reporter gene
activity appeared to be lower in these clonally derived cellFig. 2. Comparison of eGFP fluorescence and genome copy number in cells tran
these replicons. (Panel A) FACS profiles from BHK cells analyzed 48 h postelectro
and 9.4) 31 passages after isolation of G418-resistant WNV-replicon carrying colon
measured for the same cultures by dot-blot hybridization (O’Donnell et al., 20
transient, 100% for persistent colonies 7.4 and 9.4). A culture transfected with a no
RNA hybridization and eGFP fluorescence; no antigen-positive cells or viral RNA
deviations were determined using hybridization data obtained from duplicate do
genome copy number (12,300 F 900) detected in culture infected at an moi of 1 w
cells were antigen positive by IHC staining).lines than in freshly transfected cells, and individual cells
within G418-resistant cultures derived from individual
colonies expressed different levels of eGFP and antigen
through multiple passages. Furthermore, individual bclonesQ
maintained heterogeneous levels of expression through
multiple passages, and recloning these cell lines revealed
that individual cells expressing different levels of antigen
were evolving within these cultures (results not shown).
To characterize changes in replicon levels during
establishment of persistently replicating cell lines, we
carefully evaluated the evolution of cells carrying an eGFP
replicon. Specifically, we used FACS and dot-blot hybrid-
ization to quantitate the decrease in both eGFP fluorescence
and replicon copy number during the selection of clones that
stably expressed an eGFP/2A/NPT-expressing repRNA
(Fig. 2). As shown in Fig. 2A, eGFP fluorescence was
readily detectable in BHK cell cultures 48 h postelectropo-
ration. This fluorescence was specific, since no eGFP
fluorescence was detected in BHK cell cultures electro-
porated with uncapped RNA (which do not produce
antigen-positive cells (results not shown) or viral RNA
(see below; Fig. 2B). Furthermore, immunofluorescence
studies indicated that the eGFP fluorescence was only
detected in WNV antigen-positive cells (results not shown)
and the number of cells in the peak of eGFP fluorescence 48
h postelectroporation (Fig. 2A) was similar to the percent-
age of the population that was positive by IHC staining
(13% in the experiment shown in Fig. 2). Two differentsiently expressing eGFP-encoding replicons and cells persistently carrying
poration, or cultures prepared from two cloned BHK cell populations (cl. 7.4
ies. (Panel B) Genome copy number (error bars indicate standard deviation)
01) and standardized to the numbers of antigen-positive cells (12.4% for
ncapped replicon RNAwas included in both analyses to show specificity of
s were detected on this culture. Genome copy number values and standard
t-blots from the same sample. The horizontal bar in panel B the indicates
ith WNV and harvested 24 h postinfection (at this time point, 100% of the
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BHK cells electroporated with this same replicon RNA
displayed an eGFP fluorescence intensity at least five times
lower than that obtained in cells at 48 h postelectroporation
(Fig. 2A). The level of eGFP fluorescence detected in these
persistently expressing cell lines was so low that it was
difficult to readily distinguish a peak of fluorescence from
the background levels of fluorescence detected in untrans-
fected cell cultures or cells electroporated with uncapped
replicon RNA, despite the fact that 100% of these cells were
positive for WNV antigen by IHC staining (Fig. 2A). The
amount of replicon RNA in these cultures paralleled the
eGFP fluorescence data, revealing an RNA genome number
of about 8000 copies per transfected cell at 48 h post-
electroporation and about 1000 copies per cell in the two
persistent cell lines (Fig. 2B). The assay we used to detect
RNA only measured replicating RNA in the transfected
cultures, since it failed to detect RNA in cells 48 h after
transfection with an uncapped RNA (presumably due to
clearance of the RNA in the absence of replication;
consistent with the recent report of Lo et al., 2003a).
Furthermore, the level of replicon RNA observed in cultures
transiently expressing the WNV replicons was nearly as
high as the level observed in BHK cells 24 h postinfection
with WNV (see horizontal bar in Fig. 2B). Further analyses
of RNA levels within infected cells demonstrated that the
level of RNA in WNV-infected cells increased from 24 to
57 h (Table 1). This increase in cell-associated viral RNA is
most likely due to accumulation of intracellular immature
viral particles (rather than actively replicating genomes),
consistent with the delayed appearance of RNA and
infectious virus in the cell culture supernatant (Table 1).
Thus, the levels of RNA detected in replicon-expressing
cells 48 h postelectroporation are consistent with those
expressed in virus-infected cells and much higher than those
found in cells that persistently carried our WNV replicon.Table 1
Determination of genome copy number in BHK cell monolayers and supernatant
Time
postinfection (h)
Intracellular
genomes/cellb
Ffu/cellc
12 1000 0.1
24 12,300 110
36 52,500 250
48 62,000 380
57 70,000 220
a Monolayers of BHK cells were infected at an moi of 1 and incubated at 37 8C u
and a portion was saved for subsequent titration and a portion was mixed with unin
extraction. The RNA contents of these preparations (as well as TRIzol extracts of
method described in the legend of Fig. 2.
b Number of genomes in WNV-infected cells.
c Number of focus-forming units (ffu) present in cell culture fluid, expressed in te
Vero cells, see Materials and methods).
d Number of viral genomes present in cell culture fluid, expressed in terms of in
e Number of genomes detected for each ffu detected.
f CPE observed at the time of sample collection.
g Below the level of assay detection (less than 50 genomes per cell).These results are similar to those observed during selection
of noncytopathic Sindbis virus replicons, which showed that
BHK cells selected to express noncytopathic Sindbis
replicons produced 100-fold less RNA than cells containing
the WT Sindbis virus replicons (Frolov et al., 1999).
Replicon-bearing BHK cells can be used as surrogates for
detecting antiviral activity
To demonstrate the usefulness of our replicon-harboring
BHK cell cultures for evaluation of antiviral compounds,
monolayers of these cells were treated with the antiviral
drug ribavirin. As shown in Fig. 3A, Western blotting
reveals the dose-dependent clearance of three major WNV
nonstructural antigens from these cells by treatment with
ribavirin. These studies, which were conducted in the
absence of G418 (withdrawn 24 h prior to antiviral
addition), failed to reveal any ribavirin-associated changes
in cell morphology at the light microscope level. The 50%
effective concentration (EC50) of ribavirin in this experi-
ment (90 AM) is similar to that reported for WNV growth in
oligodendroglial cells (Jordan et al., 2000) and Vero cells
(Crance et al., 2003). In our experiments, we noted a
ribavirin-mediated inhibition of cell growth at concentra-
tions above 90 AM that have also been previously reported
(Crance et al., 2003). To control for this inhibition of
growth, the wells in the gel used to prepare the Western blot
in Fig. 3A were loaded with equal amounts of cell protein
(confirmed by reprobing the blot with an antibody to a
housekeeping protein h-actin; Fig. 3A), so that differences
in replicon-encoded antigen levels resulting from drug
treatment represent a specific effect of ribavirin on the
replicon. However, it is possible that the pleiotropic effects
of ribavirin on cellular metabolism at high doses could
contribute, in part, to the reduction in antigen levels seen in
Fig. 3A. Furthermore, the loss of antigen was due to drugfluids harvested at different times postinfection with WNVa
Extracellular
Genomes/celld Genomes/ffue CPEf
NDg ND None
2100 19 None
8500 34 +
12,400 33 ++
17,000 77 +++
ntil the indicated time points. The supernatant was then removed, clarified
fected cells (to provide a carrier for RNA recovery) and subjected to TRIzo
the infected monolayers) were determined using the dot-blot hybridization
rms of infected cell number (determined by immunohistochemical assay on
fected cell number.,
l
Fig. 3. Effect of ribavirin treatment on replicon-encoded antigen levels.
(Panel A) Western blot prepared from cell lysates obtained from WT BHK
or BHK clone 11.1 cells (with GFP-2A-NPT minipolyprotein gene;
passage 6) treated with different concentrations of ribavirin. Cell mono-
layers were treated with the indicated concentrations of ribavirin for 48 h,
and then washed, lysed, and 2 Ag of protein was electrophoresed side-by
side and developed with anti-WNV MHIAF (top blot) as described in
Materials and methods, or stripped and reprobed with a monoclonal
antibody that recognized h-actin (lower blot). (Panel B) ELISA showing the
effect of ribavirin on the amount of WNVantigen present in WNV-infected
BHK cells or replicon-harboring BHK cells (clone 11.1; passage 35). In the
cases of infection, cells were treated for 1 h with ribavirin and then the virus
was added for 48 h in the following amounts: 10,000 pfu (diamond) or
1,000 pfu (square). In the case of replicon-bearing cells, the cells were
treated with the indicated concentrations of ribavirin for 48 h (triangle).
Following treatment (and/or infection), the cell monolayers were fixed and
developed by an ELISA assay as described in Materials and methods; the
OD values obtained from the treated samples are expressed as a percent of
the untreated cultures (adjusted for the OD determined for uninfected
monolayers).
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selective pressure, since the culture that was not treated with
ribavirin was also cultivated in parallel in the absence of
G418 (Fig. 3A; lane 1). To compare our replicon-expressing
cells to live virus in terms of antiviral activity, a whole-cell
ELISA assay was used to compare the levels of WNV
antigen present in ribavirin-treated replicon-bearing cells or
WNV-infected cells. As can be seen in Fig. 3B, the profiles
for ribavirin-induced loss of antigen from replicon-bearing
cells and for prevention of viral infection in WT BHK cells
show a similar dose-response relationship. However, in case
of virus infection, ribavirin was more effective in preventing
the accumulation of antigen, probably due to the greater
effectiveness of this drug at the early stages of infection
(supported by the greater sensitivity of the assay under
conditions of low moi infection) or the retention of antigens
in the replicon-bearing cells expressing high levels of
antigen at the start of the 48-h antiviral treatment (Fig. 3B).Recently, Lo et al. (2003b) reported a potential high-
throughput drug-screening assay for WNV based on cells
harboring a WNV replicon encoding a Renilla luciferase
gene. We have generated similar replicon-bearing cell lines
utilizing a Luc-2A-NPT minipolyprotein gene-bearing
replicon. Fig. 4A shows the effect of ribavirin on antigen
and Luc activity for a cell line (BHK 26.5) expressing this
replicon. Under the conditions used for this assay, the anti-
growth effects of ribavirin had minimal effects on cell
number (as shown by MTT absorbance data), but reduced
both antigen level and Luc activity (Fig. 4A). These data
also demonstrate that Luc activity was more sensitive to
drug treatment than was the level of viral antigen,
suggesting that Luc was turned over more rapidly than the
repRNA-encoded viral antigen, consistent with the short
half-life of Luc in mammalian cells (Thompson et al., 1991).
Analyses of mycophenolic acid and 6-azauridine, two other
antiviral compounds known to have activity against WNV
(Morrey et al., 2002), showed that these compounds also
inhibited replicon reporter gene activity and antigen levels
in BHK 26.5 cells (Figs. 4B and C).
Vero and Huh 7 cell lines expressing replicon RNAs were
difficult to isolate
Replicon RNAs could also be introduced into Vero and
Huh7 cells by electroporation, readily producing antigen-
positive cells. However, replicon-bearing clones of Vero
cells were obtained at a very low frequency, with less than
0.05% of antigen-positive cells placed under selection
yielding colonies that persistently replicated repRNAs.
Thus, recovery of replicon-bearing Vero cell clones was
100 times less frequent than in the case of BHK cells.
Although we did not rigorously investigate the reason for
the low recovery of replicon-positive cells, it appears to
have been due, in part, to the difficulty of growing our Vero
cells at the low density required for colony formation. In the
case of Huh7 cells, the frequency of obtaining replicon-
bearing, G418-resistant colonies was even lower than that
observed for Vero cells. However, the block in obtaining
stable Huh7 cells that harbored the WNV repRNA did not
appear to be due to a difficulty in obtaining clones of this
cell type, since we were readily able to obtain G418-
resistant HCV repRNA clones in side-by-side electropora-
tion with a HepC replicon carrying the exact same tat-2A-
NPT selectable marker gene cassette (Yi et al., 2002) (results
not shown). Thus, the block in obtaining stable Huh7 cells
expressing our replicon appears to be at another level,
possibly the interaction of the cell’s antiviral response with
the replicon. Despite these impediments to obtaining
primate cells that continuously replicated our WNV
repRNA, several clones of these human and monkey cells
bearing replicons were obtained.
Once obtained, clones of Huh7 and Vero cells containing
either tat-2A-NPT or eGFP-2A-NPT stably maintained
resistance to G418 for dozens of passages, although as
Fig. 4. Effect of antiviral treatment on replicon-encoded luciferase activity from BHK clone 26.5 cells bearing the Luc-2A-NPT replicon. Monolayers of BHK
clone 26.5 cells (in 24-well plates) were treated for 48 h with varying concentrations of antiviral compounds and then lysed, or analyzed for live cell number
using MTT (as described in Materials and methods). Antigen present in 2 Ag of total cellular protein was quantitated by ELISA and is displayed as the percent
of the value obtained from lysates prepared from untreated monolayers of cells. Luciferase standardized to amount of total cellular protein recovered in each
lysate is displayed as the percent of the value obtained from lysates prepared from untreated monolayers. Panel A, effect of ribavirin treatment on cells
(passage 11). Panel B, effect of mycophenolic acid treatment on cells (passage 25). Panel C, effect of 6-azauridine treatment on cells (passage 25).
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within the Vero and Huh7 cultures displayed variable levels
of antigen expression. In the case of cells harboring eGFP-
encoding replicons, the eGFP expression was at barely
detectable levels, being dramatically reduced relative to the
levels detected in freshly transfected cells. The Western blot
in Fig. 5 demonstrates that replicon-bearing cells have lower
levels of WNV antigen than infected cells, consistent with
the reduction in antigen and eGFP fluorescence during
clonal selection of BHK cells (Fig. 2). Interestingly, the
replicons present in Huh7 clone 1.1 cells selected under
these conditions had acquired several changes in their
genomes during the cloning process (results not shown).Fig. 5. Western blot comparing WNV antigens present in samples prepared
from WT or virus-infected Huh7 and Vero cells and replicon-harboring
clones of Huh7 (clone 1.1) and Vero cells (clone 2.1 and 2.7) at passages
10, 10, and 6, respectively. Blots were prepared as described in Fig. 3A; in
the case of infected cells, the cells were infected at an moi that produced
100% antigen-positive cells in parallel monolayers and harvested 24 h
postinfection.These changes were associated with a specific adaptation to
persistent replication that was readily demonstrated by
reintroduction of total cellular RNA from the clone 1.1
cells into naive Huh7 cells. These experiments showed that
over 50% of cells successfully transfected with the clone
1.1-adapted replicon RNAwere able to form colonies in the
presence of G418, demonstrating that the clone 1.1-adapted
replicon had acquired an approximately 1000-fold increase
in colony-forming ability relative to its parental tat-2A-NPT
replicon derived directly from T7 transcription reactions
(see above).
Interferon can reduce antigen expression in WNV-replicon
bearing primate cells
Several investigators have shown that IFN is able to clear
HCV replicons from cell lines that persistently carry these
replicons (Blight et al., 2000; Lanford et al., 2003; Yi et al.,
2002). Fig. 6A shows that a single treatment of IFN was
able to reduce the levels of WNV antigen present in Vero
and Huh7 cell carrying our replicon. In terms of the potency
of IFN in this format, the amounts required to reduce
antigen levels were similar to those needed to prevent
plaque formation on monolayers of Huh7 cells infected with
live WNV of the same genetic lineage (see Fig. 6B). At
these IFN levels, antigen expression was not completely
cleared from replicon-bearing cells in a single treatment of
3 days (Fig. 6A and results not shown). However, multiple
treatments at 100 U/ml were able to clear all detectable
antigen-positive cells from replicon-bearing Huh7 cell
cultures (Fig. 6C shows a representative field from a 2-
Fig. 6. Effect of IFN on WNV replicons and WNV infection. (Panel A) Effect of a 3-day treatment with IFN (Sigma a-LE) on the expression of WNVantigen
in cultures of a clone of Vero cells (clone 2.7, passage 18) and a clone of Huh7 cells (clone 1.1, passage 22) persistently replicating a WNV repRNA encoding
the tat-2A-NPT minipolyprotein gene. WNV antigen levels present in these cells were quantitated by ELISA as described in Fig. 4. (Panel B) Effect of IFN
pretreatment on WNV focus formation on Huh7 monolayers. Duplicate monolayers of cells were treated for 18 h at the indicated concentrations of IFN,
infected with approximately 20 ffu of WNV, overlaid with media containing gum tragacanth, fixed 48 h later, and stained by IHC. IHC-stained foci were then
counted, and the results are displayed as the percent of ffu obtained in untreated wells. (Panel C) IHC staining of monolayers demonstrating replicon curing
achieved by treatment of Huh7 clone 1.1 cells for three passages (passage numbers 37–39) in the indicated concentrations of IFN.
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cells, none of which were antigen positive by IHC staining).
The reduction in antigen levels observed in replicon-bearing
cells following 72-h treatment occurred in the absence of
any loss of viable cells (measured by MTT viability assays)
and replicon clearance was not associated with induction of
apoptosis (as detected with TUNEL staining) (results not
shown).
The ease with which IFN reduced WNV antigen
expression in our replicon-bearing Vero and Huh7 cell
lines appears to be inconsistent with the work of Munoz-
Jordan et al. (2003) indicating that DV nonstructuralproteins inhibit the IFN response in cells (see Introduc-
tion). Therefore, to further evaluate if our repRNAs were
interfering with IFN action, we examined the ability of a
Luc reporter plasmid (pISRE-Luc, Stratagene, La Jolla, CA)
encoding Luc behind a pentamer of IFN-stimulated regu-
latory elements (ISRE) to be stimulated by IFN in Huh7
clone 1.1 cells bearing the repRNA and IFN-cured
derivatives of these cells. Fig. 7 shows that our replicon-
bearing cells displayed a reduced response to IFN when
compared to their cured derivatives. This difference, which
was statistically significant (see Fig. 7), was observed in
three independent experiments. In addition, WT and cured
Fig. 7. Induction of ISRE-driven Luc activity in repRNA expressing Huh7
clone 1.1 cells and a cured derivative of this cell line (created by multiple
passage in 200 U/ml of IFN a-LE). Monolayers of the indicated Huh7
cell lines were transfected with a mixture of pISRE-Luc and pCMV-
hGAL, treated for 16 h with IFN (Sigma IFN a-LE) at the indicated
concentrations, and then rinsed, solubilized, and assayed for Luc or h-
galactosidase (h-gal) activity (see Materials and methods). Luc activity in
RLU is expressed in terms of milliunits of h-gal activity recovered in the
same sample, and values from duplicate wells were used to produce the
average values shown (error bars show standard deviations). Student’s t test
demonstrated that differences in Luc induction between cured and cloned
cells were significant at each of the IFN concentrations tested (*P b 0.01;
**P b 0.005).
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shown).Discussion
Replicons have been described for several different
flaviviruses and have proven useful for the evaluation of
several aspects of the viral replication cycle (see Introduc-
tion). Here we describe the development of a WNV replicon
and infectious cDNA derived from an isolate of WNV
obtained from an immunocompromised patient. Using this
replicon, we have begun to characterize the interaction of
the WNV genome with cells in culture. These studies have
revealed that the ability to generate stable cell lines
expressing the replicons was highly dependent on cell type.
In the case of BHK cells, stable replicon-bearing cell lines
were obtained from up to 10% of the cells that stained
positive for antigen at day 2 postelectroporation. Further-
more, by carefully monitoring antigen, reporter gene
activity, and genome copy number, we discovered that cells
in these stable cell lines contained fewer replicon genomes
than in the cells in freshly electroporated cultures. In the
case of Vero and Huh7 cells, the isolation of cell lines that
stably maintained the replicon was much more difficult
(development of replicon-bearing colonies from antigen-
positive cells was over 100 times less frequent than in BHK
cells). These results stand in contrast to reports of
Mackenzie et al. (2001) and Varnavski et al. (2000) that
do not indicate any difficulty obtaining Vero cells persis-
tently expressing KV replicons. Despite the difficulty ofobtaining cells expressing our replicons, once isolated,
WNV replicon-bearing Huh7 and Vero cells stably
expressed the replicons, even in the absence of antibiotic
selection (up to eight passages, carried out biweekly for 4
weeks; results not shown). Our results add to those
produced by other investigators who have reported the
generation or cells that can stably maintain flavivirus
replicons. Using KV replicons, Varnavski et al. (2000) have
reported that h-gal activity in BHK cells transiently
expressing a h-gal-encoding KV replicon was similar (on
a per-cell basis) to the levels detected in persistently
expressing cultures. However, in another publication from
this laboratory, these researchers reported that Vero cells
persistently expressing a KV replicon produced KV antigen
and RNA at levels significantly lower than KV-infected
cells (Mackenzie et al., 2001), consistent with the results we
have obtained with our WNV replicons. In the case of a
replicon derived from a strain of WNV closely related to the
one used in our studies, Lo et al. (2003b) reported the stable
expression of Renilla luciferase through multiple passages
of a BHK cell line persistently expressing the replicon.
However, these researchers did not report bper cellQ genome
copy number and reporter gene activity in their transiently
expressing cultures (Lo et al., 2003b), so it is not possible to
determine if their persistently expressing cell lines produce
lower replicon copy numbers than their transiently express-
ing cultures. Thus, it is not possible to determine if there are
significant disparities between our work and the work of
others, but if there are, these variations could be due to
differences between the particular isolates of virus used to
generate the replicons or variations between the precise cells
utilized or the methods used to derive the cell lines that
persistently express the replicon RNAs.
The barriers to establishment of antibiotic-resistant
replicon-expressing colonies of mammalian cells could be
multifold and include replicon-mediated cell destruction and
the anti-viral response of the cells. The antiviral responses
can be further subdivided into responses that eliminate the
replicon (rendering the cells sensitive to antibiotic) and
responses that induce apoptosis (killing the replicon-bearing
cells). In several viral systems, induction of antiviral
responses, including production of IFN in association with
dsRNA, can induce apoptosis (Roulston et al., 1999), and a
number of flaviviruses have been shown to induce apoptosis
in mammalian cells in vitro (Despres et al., 1996; Liao et al.,
1998; Marianneau et al., 1998; Prikhod’ko et al., 2001) and
in vivo (Despres et al., 1998; Xiao et al., 2001a, 2001b). In
some cases, individual nonstructural proteins (dos Santos et
al., 2000; Prikhod’ko et al., 2002) have been implicated in
induction of apoptosis, but the mechanisms by which
flaviviruses and their proteins initiate apoptosis are not
fully characterized, and there appear to be large differences
between cell types and viral strains. Interestingly, the
induction of apoptosis in WNV-infected Vero cells has been
reported to be dependent on the moi used to infect the cells
(Chu and Ng, 2003), and we have detected apoptosis in cells
S.L. Rossi et al. / Virology 331 (2005) 457–470466transiently expressing WNV replicons (F. Scholle and
PWM; results not shown). Thus, the ability of replicon-
bearing cells to avoid apoptosis could be dependent on the
selection of cells with reduced genome copy number,
consistent with the data presented in the manuscript.
Moreover, analyses of the replicons that were successfully
established in one Huh7 clone under these conditions
demonstrated that the replicon RNA had undergone specific
changes that increased its ability to form colonies in naive
Huh7 cells by approximately 1000-fold, clearly demonstrat-
ing that the selected replicon contained genetic changes that
resulted in a specific adaptation to persistently replicate in
these cells. This phenotypic change in the properties of the
replicon RNA was accompanied by several changes in its
nucleotide sequence, and experiments are currently under-
way to determine which of these changes are responsible for
the adapted phenotype.
Our replicon-bearing cells can be used as surrogates for
the evaluation of antiviral activity. Consistent with recently
reported results of Lo et al. (2003b) on the use of replicon-
bearing cells for high-throughput screening of compounds
for anti-WNV activity, we have demonstrated that our
replicons are sensitive to three different antiviral com-
pounds. In our assays, these three compounds (ribavirin,
mycophenolic acid, and 6-azauridine) reduce replicon
expression with EC50 values similar to those determined
for WNV infection in vitro (Morrey et al., 2002) and with
the renilla-luciferase-expressing replicons developed by Lo
et al. (2003b). Treatment of our replicon-bearing primate
cells with IFN also resulted in suppression of antigen levels,
and repeated treatment resulted in the loss of any detectable
replicon activity, demonstrating that our replicon-bearing
cell lines can be used to detect activity of an entirely
different type of antiviral molecule.
The ability of IFN to readily reduce replicon expression
in our cells is quite interesting in light of recent reports
indicating that DV nonstructural proteins can inhibit the
ability of cells to respond to IFN treatment (Munoz-Jordan
et al., 2003), and appears to be inconsistent with a recent
report of Guo et al. (2003) showing it was difficult to clear
KV replicons from HeLa cells. This led us to examine the
ability of IFN to activate genes in replicon-bearing cells and
their cured derivatives. These studies demonstrated a
moderate, but significant, reduction in the ability of IFN
to stimulate ISRE-driven genes in replicon-bearing cells
when compared to their cured derivatives. Nevertheless, we
were surprised that the inhibition of IFN activity by our
replicons was so low, and that our Huh7 and Vero cells were
so much more readily cured of replicons than the HeLa cells
reported by Guo et al. (2003).
There are multiple explanations for the apparent differ-
ences between our results and those obtained by others.
First, the process of isolation of our replicon-bearing cells
could have selected a subpopulation of cells that is not
sensitive to replicon-mediated interference of IFN activa-
tion. Second, during isolation of our replicon-bearing cells,replicons with altered properties, which are impaired in their
ability to block the action of IFN, could have been selected.
Third, the anti-IFN activity of the replicon is dependent on
level of expression, and our replicon-bearing cells express
genomes and proteins at levels that only have a partial effect
on IFN-induced antiviral activities. Fourth, the different cell
lines utilized in these studies have different abilities to
interact with flavivirus genomes and their nonstructural
proteins. The selection of a bspecialQ cell type in the
derivation of our WNV replicon-bearing cells is consistent
with studies with an HCV virus replicon, showing that Huh7
cells with enhanced ability to replicate HCV replicons were
obtained from cells that had been selected for their ability to
carry HCV replicons and were then cured of the replicons
(Blight et al., 2002). On the other hand, HCV replicons have
been selected that have acquired mutations that enhance
their ability to establish replication in Huh7 cells (Blight et
al., 2000; Lohmann et al., 2001), and we have shown that
WNV replicons adapted to Huh7 cells have an enhanced
ability to form colonies when reintroduced into naive Huh7
cells. Thus, the changes in our replicons that are producing
this altered colony formation phenotype could also result in
a change in their ability to suppress the IFN response, which
is consistent with our second explanation for the differences
observed between our WNV studies and the flavivirus
studies reported by others (see above). The contributions of
these various mechanisms in controlling the interaction of
WNV replicons with cells are currently being investigated,
and the results of these studies should provide interesting
new information about how mosquito-borne flaviviruses
interact with their host cells.Materials and methods
Cell lines, plasmids, and viruses
Vero 76 cells and a TRIzol extract of Vero 76 cells
infected with an isolate of WNV obtained from an
immunocompromised patient were provided by R.B. Tesh.
BHK cells were provided by I.V. Frolov, and Huh7 cells
were provided by S.M. Lemon. The low-copy plasmid
pACNR (Ruggli et al., 1996), a derivative of pACY177
containing the origin of replication of plasmid p15A, was
obtained from I.V. Frolov. M.-Y. Yi provided the plasmid
pEt2AN (Yi et al., 2002). Plasmid pA12-hgal has been
described (Mason et al., 2002). All live WNVs used in these
studies were derived from the infectious cDNA derived
from the RNA recovered from the Vero cells cited above
(see Results).
cDNA synthesis, amplification, and cloning
TRIzol-extracted RNA obtained from Vero cells
infected with WNV was reverse transcribed with specific
oligonucleotide primers using Improm-II reverse tran-
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cDNA were amplified from this reaction utilizing a high-
fidelity polymerase (Herculase, Stratagene), and following
purification and restriction endonuclease digestion, cloned
as individual fragments into a derivative of a high-copy
plasmid (pT-EASY; Promega) in which the entire poly-
linker and lac promoter-hgal cassette had been removed
and replaced with a custom polylinker containing BamHI,
AflII, SmaI, SpeI, and XbaI restriction endonuclease sites.
Fragments were then assembled as depicted in Fig. 1 in
the low-copy plasmid pACNR. An HDV-RZ/bacteriophage
T7 terminator fragment was PCR amplified from an
FMDV replicon (Mason et al., 2002) using an overlap
PCR construction strategy (Higuchi et al., 1988) and
inserted following the WNV cDNA to permit precise
localization of the HDV-RZ cut site following the
predicted terminal U at position 11,029 of the encoded
WNV genome. The minipolyprotein gene present in
pEt2AN (Yi et al., 2002) was PCR amplified with
oligonucleotide primers containing an NsiI site, and
following digestion, inserted into an NsiI site in the
3VUTR at position 10,432 in the genome, previously
shown to be able to accommodate a foreign gene insertion
(Shi et al., 2002a). In some cases, the tat gene-encoding
region within the minipolyprotein gene was replaced with
either the eGFP gene (derived from pN1-EGFP; Clontech,
Palo Alto, CA) or the Luc gene using the PCR
amplification/endonuclease site addition strategy described
above (Higuchi et al., 1988).
RNA synthesis, transfection, and selection of G418-resistant
cells
Plasmid-derived cDNA templates were prepared by
digestion with XbaI restriction endonuclease and treatment
with mung bean exonuclease, and then transcribed using a
MegaScript T7 synthesis kit (Ambion, Austin, TX) supple-
mented with a 7-MeG cap analogue (NEB, Beverly, MA). In
the case of HDV-RZ-encoding plasmids, the templates were
linearized at a unique restriction enzyme site (SwaI)
following the HDV-RZ/T7 terminator. Fractions of the
transcription reaction containing 2–4 Ag of full-length
RNA (estimated by ethidium bromide staining following
agarose gel electrophoresis) were then directly transfected
into trypsinized and PBS-washed BHK, Huh7, or Vero cells
using a GenePulser (BioRad, Hercules, CA), using 0.4–0.45
ml of cells at a concentration of 1–2  107 cells/ml with two
pulses of 750–1500 V at 25 AF and infinite resistance.
Following 5–10 min at room temperature, cells were diluted
with growth media and plated into multiwell plates. In
typical experiments, some wells were fixed at 48 h to
determine the number of cells expressing antigen, and
portions of the remaining cells were placed under G418
selection (400 Ag/ml for BHK and Huh7 or 800 Ag/ml for
Vero), with antibiotic addition commencing 48 h after
electroporation. Media-containing antibiotics were changedevery 3–5 days, and during selection of colonies of
antibiotic resistant cells, media were supplemented with
up to 50% 0.22 unfiltered bconditionedQ media harvested
from growing cells. In some cases, the electroporated cells
were diluted prior to plating to insure that individual G418-
resistant colonies were obtained. Once identified, G418-
resistant clones were trypsinized and transferred through
various size wells until large-scale cultures were obtained.
During this process, portions of the culture were periodi-
cally evaluated for antigen expression.
Immunohistochemical staining to detect
WNV-antigen-expressing cells and plaques
Monolayers obtained from electroporated cell suspen-
sions or clonally derived cell lines (in some cases treated
with antiviral agents) were washed with PBS and fixed in
acetone/methanol (1:1 v/v) for at least 20 min at 20 8C.
After fixation, the cells were air dried, rehydrated with
PBS + 1% normal horse serum (NHS; Sigma, Saint
Louis, MO) for 10 min, and incubated with a WNV-
specific murine hyperimmune ascitic fluid (MHIAF;
provided by R.B. Tesh), followed by a peroxidase-
conjugated anti-mouse antibody. Antibodies were diluted
in PBS + 1% NHS and incubated for 30 min at room
temperature. After secondary antibody incubation and
washing, the cells were incubated with substrate for
peroxidase (Vector Laboratories, Burlingame, CA) until
color developed. Plaques formed on 0.6% tragacanth
gum-overlayed Vero cell monolayers at 48 h postinfection
were visualized using the same immunohistochemical
staining method.
Antiviral treatment of replicon-expressing cells
Replicon-harboring cell lines and wt cells were plated
in 24- or 96-well plates. Once the cells reached 80–100%
confluence (24–48 h after plating), the growth media were
removed and replaced with media containing dilutions of
ribavirin (Schering Corp., Kenilworth, NJ, USA), myco-
phenolic acid (Sigma), 6-azauridine (Sigma), or IFN (from
human leukocytes, IFN-a-Le; Sigma). After 48 h of
treatment, the monolayers were fixed as described for
ELISA or immunohistochemical analyses, or harvested for
ELISA, Luc assays, or Western blot analyses (see below).
For these assays, the amount of IFN utilized was based on
the side-by-side quantitation of IFN-a-LE with an NIH
standard of type I IFN (IFN-h from human fibroblasts
obtained from the NIAID Reference Reagent Repository;
operated by Braton Biotech, Gaithersburg, MD). IFN
titrations were performed using an in situ ELISA assay
(see below) to detect viral antigen 24 h after infection of
cell monolayers (at a multiplicity of infection (moi) of 1)
with WNV. Using this assay, 10 U/ml of IFN provided
50% protection of the Vero cell monolayers from WNV
infection.
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Protein extracts were prepared from PBS-washed mono-
layers by lysis for 30 min on ice in a detergent-containing
buffer (300 mM NaCl, 50 mM Tris–HCl, pH 7.6, 1% Triton
X-100), followed by clarification at 13,000 rpm for 15 min.
Samples were stored at 20 8C until use, and protein
content was determined utilizing the DC Protein Assay
(BioRad). Samples containing 2 Ag of protein were diluted
in LDS buffer (Invitrogen, Carlsbad, CA) containing 50 mM
DTT, heated at 68 8C, and then resolved on 4–12% Bis-Tris
LDS PAGE gels (Invitrogen) and electroblotted onto PVDF
membranes using standard methods. Blots were stained with
the polyclonal anti-WNV MHIAF followed by a goat anti-
mouse phosphatase-conjugated antibody preparation (KPL,
Gaithersburg, MD). Antibodies were diluted in blocking
buffer (0.2% I-Block Tropix, Bedford, MA; 0.1% TWEEN
20, Sigma, diluted in PBS) and the incubations were
performed for 30 min at room temperature. After incubation,
the membranes were washed and developed using NBT/
BCIP substrate as recommended by the manufacturer
(KPL). In some cases, blots were stripped and reprobed
with an antibody to h-actin (Sigma), which was detected
with a goat anti-mouse horseradish peroxidase conjugate
(KPL), that was visualized with a chemiluminescent
detection system (ECL; Amersham Biosciences, Bucking-
hamshire, UK).
ELISA to quantitate WNV antigen
ELISAs were performed directly on cell monolayers
fixed in situ on 96-well tissue culture plates or on 96-well
Immunolon II plates (Nunc) sensitized with 2 Ag of protein
extracted as described for Western blotting, except that the
triton concentration utilized was only 0.1%. In the case of
intact cells, the monolayers were fixed as described for
immunohistochemical analyses above. Following fixation
with acetone/methanol and rehydration, multiwell plates
were incubated with a mouse polyclonal anti-WNVantibody
diluted in PBS T (PBS containing 0.05% TWEEN 20) + 1%
NHS for 30 min followed by a goat anti-mouse, HRP-
conjugated anti-mouse antibody (KPL). Soluble substrate
(TMB; Sigma) was then allowed to react with the bound
enzyme for 5 min at room temperature, at which time the
reaction was terminated by addition of 1 M HCl and the
reaction product was quantitated spectrophotometrically at
450 nm. Similar methods were used to detect antigen
present in triton extracts. In each case, ELISA values were
corrected for background activity detected on uninfected
cell samples and expressed in terms of the percent of the OD
obtained with the untreated samples.
Antiviral luciferase assays
To determine the decrease of reporter gene expression
after treatment with antiviral compounds, BHK cellsexpressing the Luc-2A-NPT repRNA were treated with
antiviral compounds for 48 h and then lysed with either
reporter lysis buffer (Promega) or the ELISA lysis buffer
(described above), and assayed for protein concentration
(see above) and Luc activity (Luciferase Assay System,
Promega). For each sample, the Luc activity (standardized
to amount of protein) was determined and then expressed as
percent of activity obtained from lysates prepared from
untreated monolayers of replicon-bearing cells.
MTT assays
Live cell number was determined by incubation of cell
monolayers in 1 mg/ml of 3, [4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) for 3 h at 37 8C
followed by spectrophotometric quantitation (560 nm) of
the isopropanol-solubilized crystals of reduced MTT pro-
duced by the respiring cells.
Measurement of IFN-mediated activation of STAT activity
To measure IFN-mediated activation of STAT activity,
cells grown in 24-well plates were transfected with a
mixture of 0.5 Ag each of pISRE-Luc and pCMV-hgal
plasmids (Stratagene) using TransIT-LT1 Transfection
Reagent (Mirus, Madison, WI), and then treated 24 h later
with IFN. Following an overnight incubation, cells were
lysed in reporter lysis buffer (Promega) and assayed using
h-gal and Luc assay kits (Promega). All data are expressed
in terms of relative light units (RLU) of Luc per amount of
h-gal activity recovered in each lysate to compensate for
variability in reporter plasmid transfection efficiency bet-
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